Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/EJE-08-0365
European Journal of Endocrinology, Vol 159, Issue 4, R11-R14
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
EJE-08-0365v1
159/4/R11    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wakil, A.
Right arrow Articles by Atkin, S. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wakil, A.
Right arrow Articles by Atkin, S. L
RAPID COMMUNICATION

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Ammar Wakil, Alan S Rigby1, Andrew L Clark2, Anna Kallvikbacka-Bennett2 and Stephen L Atkin3

Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK1 Department of Academic Cardiology, University of Hull, Hull, UK2 Castle Hill Hospital, Castle Road, Cottingham, UK3 Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK

(Correspondence should be addressed to A Wakil; Email: ammar.wakil{at}gmail.com)

Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.

Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.

Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).

Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.




This article has been cited by other articles:


Home page
 Eur J EchocardiogrHome page
S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp
Role of echocardiography in toxic heart valvulopathy
Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
N. M Martin, T. Tan, and K. Meeran
Dopamine agonists and hyperprolactinaemia
BMJ, March 3, 2009; 338(mar03_3): b381 - b381.
[Full Text]

Home page
 NEJMHome page
E. R. Smith, J. Loeffler, M. Misra, S. R. Pomerantz, A. Stemmer-Rachamimov, and M. D. Post
Case 37-2008 -- A 17-Year-Old Boy with a Pituitary Tumor and Skull Abnormalities
N. Engl. J. Med., November 27, 2008; 359(22): 2367 - 2377.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 European Society of Endocrinology.